10-Q · May 11, 2026
Forte Biosciences reported a challenging quarter, with a substantial loss of $22.1 million despite maintaining $58.2 million in cash. Their lead candidate, FB102, continues in clinical trials with no revenue generated,…
Earnings analysis · 10-Q
FBRX earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
The filing does not provide quarterly revenue, margins, EPS, segment results, operating cash flow or free cash flow, preventing a period-over-period earnings trend assessment. Liquidity is a near-term positive, with…
Read full summary
The filing does not provide quarterly revenue, margins, EPS, segment results, operating cash flow or free cash flow, preventing a period-over-period earnings trend assessment. Liquidity is a near-term positive, with approximately $198.5 million of cash and investments and a stated runway of at least 12 months, supported by a $172.5 million April equity offering and a $500.0 million shelf registration. However, Forte remains an unprofitable, single-asset clinical-stage company with a $45.5 million six-month net loss, and the pending argenx transaction introduces substantial closing, execution and valuation risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
$198.5M liquidity supports 12-month runway
Forte reported approximately $198.5 million of cash, cash equivalents and short-term investments as of June 30, 2026, and expects existing resources to fund operations for at least 12 months from the filing date.
-
$172.5M equity raise completed
Forte closed a 2026 Offering generating $172.5 million of gross proceeds, though underwriting discounts, commissions and offering expenses were approximately $11.1 million.
-
FB102 clinical program advanced
Forte reported positive topline data from the FB102 Phase 1b vitiligo trial in July 2026 and is conducting a Phase 2 celiac study and a Phase 1b alopecia areata trial, with topline readouts expected in the second half of 2026.
-
Lean 23-person organization
Forte had 23 full-time employees as of June 30, 2026, highlighting a lean operating structure relative to its planned Phase 2 and Phase 1b development activities.
-
$500M financing capacity available
Forte filed a shelf registration statement for up to $500.0 million of securities in June 2026, preserving access to additional financing if needed.
What to watch
-
Merger completion remains uncertain
The proposed argenx transaction is expected to close in Q3 2026 but remains subject to conditions including tenders representing at least one share more than 50% of outstanding shares, regulatory clearances and other approvals. If terminated under specified circumstances, Forte may owe argenx a $65 million termination fee.
-
Continued losses require future funding
Forte states that it will require additional capital to complete FB102 clinical development despite having approximately $198.5 million of cash, cash equivalents and short-term investments as of June 30, 2026. The company reported a $45.5 million net loss for the six months ended June 30, 2026.
-
Single-asset clinical concentration
Forte’s long-term prospects depend on a single product candidate, FB102, which has no approved products behind it. FB102 remains in a Phase 2 celiac study and a Phase 1b alopecia areata study, so positive Phase 1b data from celiac disease in June 2025 and vitiligo in July 2026 may not predict later-stage outcomes.
-
Transaction disruption and retention risk
The pending transaction may restrict business activity and divert management attention; Forte has 23 full-time employees as of June 30, 2026, increasing potential execution and retention sensitivity during the transaction period.
-
Deal-break risk to equity value
Forte’s common stock closed at $76.79 per share on August 7, 2026, while the proposed transaction is exposed to a significant decline if the Offer or Merger is not completed during the expected Q3 2026 timeframe.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management expects the argenx Offer and Merger to close during Q3 2026, and expects topline readouts from the FB102 Phase 1b alopecia areata trial and Phase 2 celiac study in the second half of 2026.
Earlier filings 4
10-K · March 31, 2026
Forte Biosciences (FBRX) is a clinical-stage biopharmaceutical company focused on FB102, an anti-CD122 monoclonal antibody. The 10-K highlights positive Phase 1b celiac data (VCIEL p=0.0099) and progression to a Phase 2…
10-Q · August 14, 2025
Forte (FBRX) reported no product revenue and posted a Q2 net loss of $11,249 (three months) or $(0.96) per share, an improvement versus the prior-year quarter net loss of $12,511 and EPS $(6.78). Cash increased…
10-K · March 28, 2025
Forte is a clinical-stage biotech focused on FB102, an anti-CD122 monoclonal antibody that completed Phase 1 healthy volunteer cohorts with no dose-limiting toxicities and demonstrated pharmacodynamic signals (NK…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.